Abstract
In order to obtain prognostic clinicopathological information, 49 cases of pure ductal carcinoma in situ of the breast (DCIS), were evaluated for the immunohistochemical expression of potential predictor markers including c- erbB-2 oncogene product, p53 protein, oestrogen (ER) and progesterone (PR) receptors, oestrogen-regulated proteins pS2 and cathepsin-D (cath-D), CD44 protein and 67-kDa laminin receptor (MLuC5). Immunohistochemical findings were compared with conventional pathological parameters, clinical findings, and the clinical outcome of the patients. When markers were matched to each other, statistical analyses provided a significant positive correlation between c-erbB-2 overexpression and p53 positivity (P <0.01) and between ER and PR (P <0.01), ER, PR and pS2 (P <0.01), pS2 and MLuC5 (P <0.05). Significant negative correlations between c-erbB-2 overexpression and ER (P <0.05), PR (P <0.01) and pS2 (P <0.01) positivity was also observed. Data on the relationship between marker status and pathological findings revealed a significant positive trend between c-erbB-2, p53, and increased grade values (P <0.05) and opposite results with PR receptor expression (P <0.01). c- erbB-2 overexpression was further significantly associated with comedotype carcinoma (P <0.05) and distribution of disease in confluent neoplastic ducts (P <0.01). Although no statistically significant correlation among biological markers expression, clinical findings and outcome was demonstrated, overall this study indicates that tumour cells from a subset of DCIS, which includes comedotype carcinoma, express significantly unfavourable prognostic factors.
| Original language | English |
|---|---|
| Pages (from-to) | 1148-1155 |
| Number of pages | 8 |
| Journal | European Journal of Cancer |
| Volume | 32 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - Jun 1996 |
Fingerprint
Keywords
- c-erbB-2
- cath-D
- CD44
- ductal carcinoma in situ of the breast
- ER
- MLuC5
- p53
- PR
- pS2
ASJC Scopus subject areas
- Cancer Research
- Hematology
- Oncology
Cite this
Immunohistochemical evaluation of multiple biological markers in ductal carcinoma in situ of the breast. / Perin, T.; Canzonieri, V.; Massarut, S.; Bidoli, E.; Rossi, C.; Roncadin, M.; Carbone, A.
In: European Journal of Cancer, Vol. 32, No. 7, 06.1996, p. 1148-1155.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Immunohistochemical evaluation of multiple biological markers in ductal carcinoma in situ of the breast
AU - Perin, T.
AU - Canzonieri, V.
AU - Massarut, S.
AU - Bidoli, E.
AU - Rossi, C.
AU - Roncadin, M.
AU - Carbone, A.
PY - 1996/6
Y1 - 1996/6
N2 - In order to obtain prognostic clinicopathological information, 49 cases of pure ductal carcinoma in situ of the breast (DCIS), were evaluated for the immunohistochemical expression of potential predictor markers including c- erbB-2 oncogene product, p53 protein, oestrogen (ER) and progesterone (PR) receptors, oestrogen-regulated proteins pS2 and cathepsin-D (cath-D), CD44 protein and 67-kDa laminin receptor (MLuC5). Immunohistochemical findings were compared with conventional pathological parameters, clinical findings, and the clinical outcome of the patients. When markers were matched to each other, statistical analyses provided a significant positive correlation between c-erbB-2 overexpression and p53 positivity (P <0.01) and between ER and PR (P <0.01), ER, PR and pS2 (P <0.01), pS2 and MLuC5 (P <0.05). Significant negative correlations between c-erbB-2 overexpression and ER (P <0.05), PR (P <0.01) and pS2 (P <0.01) positivity was also observed. Data on the relationship between marker status and pathological findings revealed a significant positive trend between c-erbB-2, p53, and increased grade values (P <0.05) and opposite results with PR receptor expression (P <0.01). c- erbB-2 overexpression was further significantly associated with comedotype carcinoma (P <0.05) and distribution of disease in confluent neoplastic ducts (P <0.01). Although no statistically significant correlation among biological markers expression, clinical findings and outcome was demonstrated, overall this study indicates that tumour cells from a subset of DCIS, which includes comedotype carcinoma, express significantly unfavourable prognostic factors.
AB - In order to obtain prognostic clinicopathological information, 49 cases of pure ductal carcinoma in situ of the breast (DCIS), were evaluated for the immunohistochemical expression of potential predictor markers including c- erbB-2 oncogene product, p53 protein, oestrogen (ER) and progesterone (PR) receptors, oestrogen-regulated proteins pS2 and cathepsin-D (cath-D), CD44 protein and 67-kDa laminin receptor (MLuC5). Immunohistochemical findings were compared with conventional pathological parameters, clinical findings, and the clinical outcome of the patients. When markers were matched to each other, statistical analyses provided a significant positive correlation between c-erbB-2 overexpression and p53 positivity (P <0.01) and between ER and PR (P <0.01), ER, PR and pS2 (P <0.01), pS2 and MLuC5 (P <0.05). Significant negative correlations between c-erbB-2 overexpression and ER (P <0.05), PR (P <0.01) and pS2 (P <0.01) positivity was also observed. Data on the relationship between marker status and pathological findings revealed a significant positive trend between c-erbB-2, p53, and increased grade values (P <0.05) and opposite results with PR receptor expression (P <0.01). c- erbB-2 overexpression was further significantly associated with comedotype carcinoma (P <0.05) and distribution of disease in confluent neoplastic ducts (P <0.01). Although no statistically significant correlation among biological markers expression, clinical findings and outcome was demonstrated, overall this study indicates that tumour cells from a subset of DCIS, which includes comedotype carcinoma, express significantly unfavourable prognostic factors.
KW - c-erbB-2
KW - cath-D
KW - CD44
KW - ductal carcinoma in situ of the breast
KW - ER
KW - MLuC5
KW - p53
KW - PR
KW - pS2
UR - http://www.scopus.com/inward/record.url?scp=0030176129&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030176129&partnerID=8YFLogxK
U2 - 10.1016/0959-8049(96)00037-8
DO - 10.1016/0959-8049(96)00037-8
M3 - Article
C2 - 8758245
AN - SCOPUS:0030176129
VL - 32
SP - 1148
EP - 1155
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
IS - 7
ER -